IOLCP — IOL Chemicals and Pharmaceuticals Balance Sheet
0.000.00%
- IN₹38.65bn
- IN₹37.91bn
- IN₹23.19bn
Annual balance sheet for IOL Chemicals and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,417 | 231 | 1,428 | 2,093 | 2,093 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,141 | 5,525 | 5,263 | 5,635 | 6,031 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 10,808 | 9,204 | 11,198 | 11,513 | 12,276 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,625 | 8,326 | 10,214 | 11,792 | 12,624 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 19,623 | 20,221 | 22,444 | 23,821 | 25,870 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5,134 | 4,563 | 5,600 | 6,099 | 6,902 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5,700 | 5,144 | 6,329 | 6,944 | 7,884 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 13,923 | 15,077 | 16,115 | 16,877 | 17,986 |
| Total Liabilities & Shareholders' Equity | 19,623 | 20,221 | 22,444 | 23,821 | 25,870 |
| Total Common Shares Outstanding |